EAM
SLS icon

Empery Asset Management’s SELLAS Life Sciences SLS Stock Holding History

Empery Asset Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$623K Sell
308,466
-619,518
-67% -$1.71M 3.71% 9
2022
Q2 		$2.07M Buy
+927,984
New +$2.72M 11.2% 3

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EH
Equitable Holdings New York $16.7B AUM 24.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Empery Asset Management's SLS Position: Q3 2022 in Review

Empery Asset Management reduced its SELLAS Life Sciences (SLS) stake by 67% in Q3 2022, selling an estimated $1.71M and leaving 308,466 shares worth $623K. The position accounts for 3.71% of the portfolio, ranked #9.

Empery Asset Management first reported a position in SLS in Q2 2022 and has held it in 2 quarters since. The position peaked at $2.07M in Q2 2022. 28 funds tracked by Wall St. Rank hold SLS as of Q3 2022.

  • Empery Asset Management held 308,466 shares of SELLAS Life Sciences worth $623K as of Q3 2022.
  • Empery Asset Management sold 619,518 SELLAS Life Sciences shares in Q3 2022, an estimated $1.71M.
  • SELLAS Life Sciences made up 3.71% of Empery Asset Management's portfolio in Q3 2022, its #9 holding.
  • Empery Asset Management first reported a position in SELLAS Life Sciences in Q2 2022 and has held it in 2 quarters since.
  • Empery Asset Management's SELLAS Life Sciences position peaked at $2.07M in Q2 2022.
  • 28 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2022.

Based on Empery Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.